Cisplatin (Platinol)

General information

Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.
Route: IV, intracavitary (intraperitoneal)
Extravasation: vesicant (concentration ≥0.5 mg/mL)/irritant (concentration <0.5 mg/mL)

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Carcinoma of unknown primary
• Adrenocortical carcinoma
• Anal cancer
• Anaplastic large cell lymphoma
• Cutaneous basal cell carcinoma
• Bladder cancer
• Breast cancer
• Cervical cancer
• Cholangiocarcinoma
• Diffuse large B-cell lymphoma
• Endometrial cancer
• Esophageal cancer
• Extranodal NK- and T-cell lymphoma, nasal type
• Gastric cancer
• Head and neck cancer
• Hepatoblastoma
• Hodgkin lymphoma
• Low-grade glioma
• Mantle cell lymphoma
• Melanoma
• Mesothelioma
• Multiple myeloma
• Nasopharyngeal carcinoma
• Non-small cell lung cancer
• Osteosarcoma
• Ovarian cancer
• Pancreatic cancer
• Penile cancer
• Peripheral T-cell lymphoma
• Primary mediastinal B-cell lymphoma
• SCC of unknown primary
• Small cell lung cancer
• Cutaneous squamous cell carcinoma
• Testicular cancer
• Thymoma
• Transformed lymphoma
• Upper tract urothelial carcinoma
• Vulvar cancer

Patient drug information

• Cisplatin (Platinol) package insert
• Cisplatin (Platinol) patient drug information (Chemocare)
• Cisplatin (Platinol) patient drug information (UpToDate)

History of changes in FDA indication

• 12/19/1978: Initial FDA approval
• 9/2/2010: (earliest label available at Drugs@FDA) Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures.
• 9/2/2010: (earliest label available at Drugs@FDA) Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and cyclophosphamide. PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received PLATINOL therapy.
• 9/2/2010: (earliest label available at Drugs@FDA) Indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Also known as

• Code name: NSC 119875
• Generic names: CDDP, cis-diamminedichloroplatinum III, cis-platinum, cisplatinum, DACP, DDP
• Brand names:

Synonyms
Abiplatin	Axiplat	Biocisplatinum	Bioplatino	Blastolem	Briplatin	Brisplatin	C-Platin
Ceplatin	Ciplatan	Ciplexal	Cis-GRY	Cismaplat	Cispatin	Cisplamerck	Cisplan
Cisplasol	Cisplatex	Cisplatine	Cisplatino	Cisplatyl	Cisteen	Citoplatino	Citosin
Cysplatyna	Cytoplatin	Docistin	Elvecis	Fauldcispla	Ifapla	Kemoplat	Lederplatin
Metaplatin	Neoplat	Neoplatin	Noveldexis	Oncoplatin AQ	Peyrone's Chloride	Peyrone's Salt	Placis
Plastistil	Platamin	Platamine	Platiblastin	Platicis	Platidiam	Platikem	Platil
Platimit	Platin	Platinex	Platinil	Platino II Filaxis	Platinol	Platinox	Platinoxan
Platiran	Platistil	Platistin	Platistine	Platosin	Randa	Romcis	Sicatem
Sinplatin	Sisplanil	Tecnoplatin	Tisplal	Unistin